Du är här

2016-02-25

Herantis Pharma Oyj: Decision in arbitration proceedings between Herantis Pharma Plc's subsidiary Laurantis Pharma Ltd and Finvector Vision Therapies Ltd

Decision in arbitration proceedings between Herantis Pharma Plc's subsidiary
Laurantis Pharma Ltd and Finvector Vision Therapies Ltd

Herantis Pharma Plc
Company release 25 February 2016, 11:00 am

In March 2015, Finvector Vision Therapies Ltd ("Finvector") initiated
arbitration proceedings against Herantis Pharma Plc's ("Herantis") subsidiary
Laurantis Pharma Ltd ("Laurantis") and a number of its former shareholders.
Herantis holds 99.0 per cent of the shares in Laurantis. Based on an alleged
breach of a shareholders' agreement regarding Laurantis, Finvector seeked
from Laurantis and a number of its former shareholders damages in the total
amount of approximately 1,000,000 euros including interests and costs.

The Finnish Court of Arbitration has given its final award on 25 February 2016
at 10:00am. The arbitral tribunal has held that there has been no alleged
breach of shareholders' agreement and thus Finvector is not entitled to claim
damages. Finvector's claim is dismissed in full and Finvector is obligated to
pay to Laurantis and its former shareholders as compensation for the legal
costs approximately 200,000 euro. The compensation to Laurantis is
approximately 50,000 euro.

The decision does not impact the outlook for 2016 or guidance for 2016 of
Herantis.

Further information:

Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site:www.herantis.com

Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

About Herantis Pharma Plc

Herantis Pharma Plc is a pharmaceutical company specialised in new drug
research and development. The company focuses on diseases with an unmet
clinical need. These diseases include for example Parkinson's disease and
secondary lymphedema. The shares of Herantis are listed on the First North
Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire

HUG#1989283

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.